التفاصيل البيبلوغرافية
| العنوان: |
Neurological outcome in long‐chain hydroxy fatty acid oxidation disorders. |
| المؤلفون: |
Mütze, Ulrike, Ottenberger, Alina, Gleich, Florian, Maier, Esther M., Lindner, Martin, Husain, Ralf A., Palm, Katja, Beblo, Skadi, Freisinger, Peter, Santer, René, Thimm, Eva, vom Dahl, Stephan, Weinhold, Natalie, Grohmann‐Held, Karina, Haase, Claudia, Hennermann, Julia B., Hörbe‐Blindt, Alexandra, Kamrath, Clemens, Marquardt, Iris, Marquardt, Thorsten |
| المصدر: |
Annals of Clinical & Translational Neurology; Apr2024, Vol. 11 Issue 4, p883-898, 16p |
| مصطلحات موضوعية: |
FATTY acid oxidation, HYDROXY acids, GLUCOSE-6-phosphate dehydrogenase deficiency, THERAPEUTICS, NEWBORN screening, DIET therapy |
| مستخلص: |
Objective: This study aims to elucidate the long‐term benefit of newborn screening (NBS) for individuals with long‐chain 3‐hydroxy‐acyl‐CoA dehydrogenase (LCHAD) and mitochondrial trifunctional protein (MTP) deficiency, inherited metabolic diseases included in NBS programs worldwide. Methods: German national multicenter study of individuals with confirmed LCHAD/MTP deficiency identified by NBS between 1999 and 2020 or selective metabolic screening. Analyses focused on NBS results, confirmatory diagnostics, and long‐term clinical outcomes. Results: Sixty‐seven individuals with LCHAD/MTP deficiency were included in the study, thereof 54 identified by NBS. All screened individuals with LCHAD deficiency survived, but four with MTP deficiency (14.8%) died during the study period. Despite NBS and early treatment neonatal decompensations (28%), symptomatic disease course (94%), later metabolic decompensations (80%), cardiomyopathy (28%), myopathy (82%), hepatopathy (32%), retinopathy (17%), and/or neuropathy (22%) occurred. Hospitalization rates were high (up to a mean of 2.4 times/year). Disease courses in screened individuals with LCHAD and MTP deficiency were similar except for neuropathy, occurring earlier in individuals with MTP deficiency (median 3.9 vs. 11.4 years; p = 0.0447). Achievement of dietary goals decreased with age, from 75% in the first year of life to 12% at age 10, and consensus group recommendations on dietary management were often not achieved. Interpretation: While NBS and early treatment result in improved (neonatal) survival, they cannot reliably prevent long‐term morbidity in screened individuals with LCHAD/MTP deficiency, highlighting the urgent need of better therapeutic strategies and the development of disease course‐altering treatment. [ABSTRACT FROM AUTHOR] |
|
Copyright of Annals of Clinical & Translational Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder